← Leaderboards
Ami Aalok Shah
Johns Hopkins University
$3,647,591
Attributed
$5,918,355
Total exposure
3
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $910.4K · FY2012–25$1M$750K$500K$250K$0
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$5,918,355 · 3
By mechanism
R01$4,541,529 · 1
K23$699,182 · 1
K24$677,644 · 1
Top collaborators
- Livia A Casciola-Rosen7 shared
Most similar at Johns Hopkins University
Same institution · by research overlap
- Joel F Schildbach$3,257,392
- Livia A Casciola-Rosen$11,279,825
- Antony Rosen$15,771,548
- Drew M. Pardoll$27,059,898
- Elizabeth Marion Jaffee$29,780,612
Others in their field
Top investigators on “Insight”
- Sonia M Thomas · Research Triangle Institute$701,865,642
- Tracy L Nolen · Research Triangle Institute$474,487,152
- James Dennis Neaton · Northwestern University$283,212,546
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$278,513,775
- Chanza Baytop · Westat, Inc.$271,217,917
- Richard K. Wilson · Washington University$200,435,757
Research focus
InsightImmune ResponseAutoantibodiesMalignant NeoplasmsPhenotypeRheumatismSclerodermaClinically RelevantAutoantigensCohortCancer RiskResponseComplexPathogenesisScreeningRisk FactorsFoundationsScreening For CancerAntibodiesPatternLinkPatient SubsetsRna Polymerase IiiSpecificity
Grant awards (17)
Autoantibodies define scleroderma subgroups with distinct relationships to cancer$635,462
R01 · FY2025 · AR · contact PI
Harnessing multivariate patient- and population-level disease trajectories to predict major clinical events in scleroderma$169,411
K24 · FY2025 · AR · contact PI
Autoantibodies define scleroderma subgroups with distinct relationships to cancer$741,025
R01 · FY2024 · AR · contact PI
Harnessing multivariate patient- and population-level disease trajectories to predict major clinical events in scleroderma$169,411
K24 · FY2024 · AR · contact PI
Harnessing multivariate patient- and population-level disease trajectories to predict major clinical events in scleroderma$169,411
K24 · FY2023 · AR · contact PI
Autoantibodies Define Scleroderma Subgroups with Distinct Relationships to Cancer$613,058
R01 · FY2022 · AR · contact PI
Harnessing multivariate patient- and population-level disease trajectories to predict major clinical events in scleroderma$169,411
K24 · FY2022 · AR · contact PI
Autoantibodies Define Scleroderma Subgroups with Distinct Relationships to Cancer$616,811
R01 · FY2021 · AR · contact PI
Autoantibodies Define Scleroderma Subgroups with Distinct Relationships to Cancer$636,081
R01 · FY2020 · AR · contact PI
Autoantibodies Define Scleroderma Subgroups with Distinct Relationships to Cancer$634,533
R01 · FY2019 · AR · contact PI
Autoantibodies Define Scleroderma Subgroups with Distinct Relationships to Cancer$664,559
R01 · FY2018 · AR · contact PI
Cancer, Autoantigens, and Scleroderma Investigating the Connection$151,711
K23 · FY2016 · AR · contact PI
Cancer, Autoantigens, and Scleroderma Investigating the Connection$136,755
K23 · FY2015 · AR · contact PI
Cancer, Autoantigens, and Scleroderma Investigating the Connection$451
K23 · FY2015 · AR · contact PI
Cancer, Autoantigens, and Scleroderma Investigating the Connection$136,755
K23 · FY2014 · AR · contact PI
Cancer, Autoantigens, and Scleroderma Investigating the Connection$136,755
K23 · FY2013 · AR · contact PI
Cancer, Autoantigens, and Scleroderma Investigating the Connection$136,755
K23 · FY2012 · AR · contact PI